Drug Trial Radar · NCT04880031
A Study of BOS-580 in Obese Subjects at Risk for, or With Biopsy-confirmed, Nonalcoholic Steatohepatitis (NASH) With an Extension
Last checked: Nov 19, 2026Latest source record: Jul 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
231
Actual
Start
Sep 30, 2021
Primary completion
Oct 27, 2025
Study completion Oct 27, 2025
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- May 10, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, blinded, placebo-controlled study of Efimosfermin in obese participants at risk for, or with biopsy-confirmed, nonalcoholic steatohepatitis (NASH), with a single arm open-label extension. It includes Parts A, B, C and D.
Conditions
- Nonalcoholic Steatohepatitis (NASH)
Interventions
EfimosferminDrug
Efimosfermin will be administered by subcutaneous injection
PlaceboDrug
Placebo will be administered by subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A, Part B, Part C, and Part D: Number of participants with treatment-emergent adverse events (TEAEs) and treatment-emergent serious adverse events (TESAEs)Time frame: Until End of study/Early Termination (Day 393)
- Part A, Part B, Part C, and Part D: Changes from Baseline in systolic and diastolic blood pressure (BP)Time frame: Baseline, Week 12 (Day 85, Part A), Week 24 (Day 169, Part B), Week 56 (Day 393, Part C), and Weeks 36 (Day 253), and 48 (Day 337) (Part D)
- Part A, Part B, Part C, and Part D: Changes from Baseline in heart rateTime frame: Baseline, Week 12 (Day 85, Part A), Week 24 (Day 169, Part B), Week 56 (Day 393, Part C), and Weeks 36 (Day 253), and 48 (Day 337) (Part D)
- Part A, Part B, Part C, and Part D: Number of participants with Grade 3 and Grade 4 laboratory abnormalitiesTime frame: Baseline, Week 12 (Day 85, Part A), Week 24 (Day 169, Part B), Week 56 (Day 393, Part C), and Weeks 36 (Day 253), and 48 (Day 337) (Part D)
Locations
48 sites in 1 country. Site status is shown where the registry gives one.
Central Research Associates
Birmingham, Alabama
Arizona Liver Health
Chandler, Arizona
Arizona Liver Health
Peoria, Arizona
Arizona Liver Health
Tucson, Arizona
Liver Institute PPLC
Tucson, Arizona
QLMC
Tucson, Arizona
Alliance Research Institute
Canoga Park, California
Ark Clinical Research
Fountain Valley, California
Fresno Clinical Research Center
Fresno, California
Catalina Research Institute
Montclair, California
Knowledge Research Center
Orange, California
FOMAT Medical Research
Oxnard, California
Inland Empire Clinical Trials
Rialto, California
Southwest General Healthcare Center
Fort Myers, Florida
Covenant Metabolic Specialists - Fort Myers
Fort Myers, Florida
Evolution Clinical Trials
Hialeah Gardens, Florida
Entrust Clinical Research Center
Kendall, Florida
Galenus Group
Lehigh Acres, Florida
G+C Research Group
Miami, Florida
Miami Clinical Research
Miami, Florida
Advanced Clinical Research
Miami, Florida
Admed Research
Miami, Florida
Century Research
Miami, Florida
Panex Clinical Research
Miami Lakes, Florida
Charter Research
Orlando, Florida
Progressive Medical Research
Port Orange, Florida
Covenant Metabolic Specialists - Sarasota
Sarasota, Florida
Tandem Clinical Research
Marrero, Louisiana
Kansas City Research Institute
Kansas City, Missouri
Coastal Research Institute, LLC
Fayetteville, North Carolina
Lillestol Research LLC
Fargo, North Dakota
Velocity Clinical Research
East Greenwich, Rhode Island
Accelemed Research
Austin, Texas
Pinnacle Clinical Research - Austin
Austin, Texas
Texas Liver Institute - Austin
Austin, Texas
Apex Mobile Clinical Research
Bellaire, Texas
South Texas Research Institute-Brownsville
Brownsville, Texas
South Texas Research Institute-Edinburg
Edinburg, Texas
Pinnacle Clinical Research - Georgetown
Georgetown, Texas
Houston Research Institute
Houston, Texas
Showing 40 of 48 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.